Catalyst Calendar

Mon, Oct 5, 2026

1 updates

8:00 AM

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

REDWOOD CITY, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that it has begun treating

Trial Start • Phase 3Trial initiation Mon, Oct 5, 2026revmed.com

Mon, Sep 14, 2026

1 updates

RVMD

4:05 PM

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

Company receives third Breakthrough Therapy Designation for RASONQUE and fifth across its portfolio of RAS(ON) inhibitors, further highlighting its differentiated strategy for developing innovative medicines for patients with RAS-addicted cancers REDWOOD CITY, Calif., Sept.

revmed.com

Wed, Sep 2, 2026

1 updates

RVMD

5:50 PM

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a global, commercial-stage oncology company dedicated to

Trial Results • Phase 1/2NEJM publication of Phase 1/2 trial results Wed, Sep 2, 2026revmed.com

Wed, Aug 26, 2026

1 updates

RVMD

12:59 PM

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

RASONQUE is indicated for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy In the Phase 3 RASolute 302 trial, RASONQUE reduced the risk of death by 60% and

revmed.com

Mon, Aug 10, 2026

1 updates

RVMD

6:01 AM

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines

revmed.com

Wed, Aug 5, 2026

1 updates

RVMD

4:02 PM

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase 3 RASolute 302 results Rapidly implemented U.S. Expanded Access Program for eligible patients with previously treated metastatic pancreatic cancer

Trial Results • Phase 1/2Results call Wed, Aug 5, 2026, 4:30 PM ETrevmed.com

Wed, Jul 29, 2026

1 updates

RVMD

4:05 PM

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2026 on

revmed.com

Wed, Jul 22, 2026

1 updates

RVMD

4:05 PM

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the

revmed.com